- Current status
- AHSCT is a standard of care of RRMS
- Wykłady na kursie specjalizacyjnym – transplantologia
- AHSCT is better choice than DMDs in MS as a treatment of cases progressing after first line treatment – multicenter randomised trial.
- CPX-351 (Vyxeos) – new drug that improves treatment in older patients with secondary AML
Monthly Archives: April 2017
I have just returned from the EBMT 2017 conference. I have met with most prominent world scientist in field of HSCT – and I am truly amazed by the results that were presented. Here are the most important observations: CIDP … Continue reading